Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study

Launched by FONDAZIONE IRCCS SAN GERARDO DEI TINTORI · Nov 15, 2024

Keywords

ClinConnect Summary

The PREDIC-TO study is looking at how to best identify patients with Diffuse Large B-cell Lymphoma (DLBCL) who are at risk for blood clots, also known as thrombosis. Researchers want to compare several existing prediction models to see which one works best for DLBCL patients. They will collect information about both fixed factors (like age and medical history) and changing factors (like treatment response) to understand their relationship with blood clots. The ultimate goal is to create a specific model for DLBCL that can help doctors identify patients who might need extra care to prevent blood clots during treatment.

To participate in this study, you need to be at least 18 years old and have been diagnosed with DLBCL. You'll be required to give your consent to take part in the research. If you are currently on blood thinners or have started preventive treatment with heparin, you won't be eligible for this study. If you join, you'll help researchers learn more about thrombotic risks in DLBCL patients, which could lead to better treatment and care in the future. The study is currently recruiting participants, and your involvement could make a difference in improving patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects aged ≥ 18 years
• • Histological diagnosis of DLBCL
• • Informed consent freely given and obtained
• Exclusion Criteria:
• • Active anticoagulant therapy at the time of diagnosis
• • Start of prophylactic heparin following diagnosis
• • Absence of necessary data to extrapolate risk scores (Khorana, Throly and Model IX) at diagnosis